25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ANI Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze ANI Pharmaceuticals Inc together

I guess you are interested in ANI Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ANI Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ANI Pharmaceuticals Inc

I send you an email if I find something interesting about ANI Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of ANI Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of ANI Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.07
When do you have the money?
1 year
How often do you get paid?
72.7%

What is your share worth?

Current worth
€18.14
Expected worth in 1 year
€16.91
How sure are you?
59.1%

+ What do you gain per year?

Total Gains per Share
€-1.16
Return On Investment
-2.1%

For what price can you sell your share?

Current Price per Share
€56.50
Expected price per share
€51.00 - €60.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of ANI Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
€56.50
Intrinsic Value Per Share
€61.72 - €73.75
Total Value Per Share
€79.86 - €91.89

2.2. Growth of ANI Pharmaceuticals Inc (5 min.)




Is ANI Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$428.5m$421.5m$32.6m7.2%

How much money is ANI Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$4.6m$4.6m-$9.3m-201.4%
Net Profit Margin-2.5%3.8%--

How much money comes from the company's main activities?

2.3. Financial Health of ANI Pharmaceuticals Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of ANI Pharmaceuticals Inc?

Welcome investor! ANI Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of ANI Pharmaceuticals Inc.

First you should know what it really means to hold a share of ANI Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of ANI Pharmaceuticals Inc is €56.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of ANI Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in ANI Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €18.14. Based on the TTM, the Book Value Change Per Share is €-0.31 per quarter. Based on the YOY, the Book Value Change Per Share is €1.26 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.02 per quarter.
Based on historical numbers we can estimate the returns while holding a share of ANI Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.47-0.8%-0.21-0.4%0.200.4%-0.27-0.5%-0.24-0.4%
Usd Book Value Change Per Share-0.10-0.2%-0.33-0.6%1.372.4%0.500.9%0.901.6%
Usd Dividend Per Share0.020.0%0.020.0%0.020.0%0.010.0%0.010.0%
Usd Total Gains Per Share-0.09-0.2%-0.32-0.6%1.392.5%0.510.9%0.911.6%
Usd Price Per Share55.36-61.06-50.83-41.83-43.85-
Price to Earnings Ratio-29.31--42.90-135.01-130.12-119.91-
Price-to-Total Gains Ratio-647.06--67.66-262.58-305.70-111.94-
Price to Book Ratio2.81-2.92-2.62-2.85-3.18-
Price-to-Total Gains Ratio-647.06--67.66-262.58-305.70-111.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share61.33075
Number of shares16
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.01
Usd Book Value Change Per Share-0.330.50
Usd Total Gains Per Share-0.320.51
Gains per Quarter (16 shares)-5.048.14
Gains per Year (16 shares)-20.1832.55
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11-21-3013223
22-43-5026356
34-64-7029589
45-85-903127122
56-107-1104159155
67-128-1305190188
78-150-1506222221
810-171-1707254254
911-192-1907285287
1012-214-2108317320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%5.07.00.041.7%7.013.00.035.0%8.014.00.036.4%8.014.00.036.4%
Book Value Change Per Share2.02.00.050.0%7.05.00.058.3%11.09.00.055.0%12.010.00.054.5%12.010.00.054.5%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%16.00.04.080.0%16.00.06.072.7%16.00.06.072.7%
Total Gains per Share2.02.00.050.0%8.04.00.066.7%12.08.00.060.0%13.09.00.059.1%13.09.00.059.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of ANI Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.096-0.308+220%1.260-108%0.457-121%0.825-112%
Book Value Per Share--18.13919.226-6%17.845+2%13.948+30%13.500+34%
Current Ratio--2.7253.347-19%3.478-22%3.015-10%2.928-7%
Debt To Asset Ratio--0.6660.572+16%0.508+31%0.556+20%0.554+20%
Debt To Equity Ratio--1.9961.454+37%1.041+92%1.288+55%1.275+57%
Dividend Per Share--0.0170.0170%0.0170%0.012+44%0.011+59%
Enterprise Value--322112759.600627761370.000-49%620007443.900-48%456889960.520-29%511662239.945-37%
Eps---0.435-0.196-55%0.184-337%-0.246-44%-0.225-48%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--0.4591.180-61%1.368-66%1.471-69%1.862-75%
Free Cash Flow Per Share--0.5660.498+14%1.063-47%0.056+910%0.056+910%
Free Cash Flow To Equity Per Share--0.3593.302-89%1.777-80%1.157-69%1.157-69%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--73.751--------
Intrinsic Value_10Y_min--61.723--------
Intrinsic Value_1Y_max--2.278--------
Intrinsic Value_1Y_min--2.234--------
Intrinsic Value_3Y_max--10.741--------
Intrinsic Value_3Y_min--10.175--------
Intrinsic Value_5Y_max--23.901--------
Intrinsic Value_5Y_min--21.849--------
Market Cap1229586900.000+10%1109892600.0001224146250.000-9%1019033745.000+9%838621791.000+32%879110119.091+26%
Net Profit Margin---0.054-0.025-53%0.038-243%-0.092+70%-0.084+57%
Operating Margin----0%0.057-100%-0.0090%0.012-100%
Operating Ratio--1.4141.400+1%1.269+11%1.459-3%1.445-2%
Pb Ratio3.115+10%2.8122.923-4%2.616+7%2.846-1%3.182-12%
Pe Ratio-32.473-11%-29.312-42.903+46%135.009-122%130.119-123%119.912-124%
Price Per Share56.500+10%51.00056.250-9%46.825+9%38.535+32%40.395+26%
Price To Free Cash Flow Ratio24.940+10%22.51230.159-25%12.660+78%0.761+2860%0.691+3156%
Price To Total Gains Ratio-716.846-11%-647.064-67.655-90%262.578-346%305.697-312%111.936-678%
Quick Ratio--1.1771.205-2%1.310-10%1.291-9%1.246-5%
Return On Assets---0.008-0.002-71%0.005-248%-0.008+6%-0.008-2%
Return On Equity---0.024-0.012-51%0.011-323%-0.021-12%-0.019-19%
Total Gains Per Share---0.079-0.290+268%1.277-106%0.469-117%0.835-109%
Usd Book Value--428513972.978454170763.378-6%421550233.432+2%329506126.010+30%318910345.034+34%
Usd Book Value Change Per Share---0.104-0.334+220%1.368-108%0.496-121%0.895-112%
Usd Book Value Per Share--19.69020.869-6%19.370+2%15.141+30%14.654+34%
Usd Dividend Per Share--0.0190.0190%0.0190%0.013+44%0.012+59%
Usd Enterprise Value--349653400.546681434967.135-49%673018080.353-48%495954052.144-29%555409361.461-37%
Usd Eps---0.472-0.213-55%0.200-337%-0.267-44%-0.244-48%
Usd Free Cash Flow--13379499.58811765559.952+14%25111060.811-47%1324100.477+910%1203727.706+1012%
Usd Free Cash Flow Per Share--0.6150.541+14%1.154-47%0.061+910%0.061+910%
Usd Free Cash Flow To Equity Per Share--0.3893.584-89%1.929-80%1.256-69%1.256-69%
Usd Market Cap1334716579.950+10%1204788417.3001328810754.375-9%1106161130.198+9%910323954.131+32%954274034.273+26%
Usd Price Per Share61.331+10%55.36161.059-9%50.829+9%41.830+32%43.849+26%
Usd Profit---10275615.678-4630326.819-55%4694574.416-319%-5639289.083-45%-5169352.114-50%
Usd Revenue--190566872.532153588255.584+24%121699448.270+57%92105955.108+107%88246290.374+116%
Usd Total Gains Per Share---0.086-0.315+268%1.386-106%0.509-117%0.907-109%
 EOD+4 -4MRQTTM+11 -26YOY+8 -305Y+17 -2010Y+16 -22

3.3 Fundamental Score

Let's check the fundamental score of ANI Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-32.473
Price to Book Ratio (EOD)Between0-13.115
Net Profit Margin (MRQ)Greater than0-0.054
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.177
Current Ratio (MRQ)Greater than12.725
Debt to Asset Ratio (MRQ)Less than10.666
Debt to Equity Ratio (MRQ)Less than11.996
Return on Equity (MRQ)Greater than0.15-0.024
Return on Assets (MRQ)Greater than0.05-0.008
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of ANI Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose56.000
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Fundamental data was last updated by Penke on 2025-03-05 21:03:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit ANI Pharmaceuticals Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare ANI Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -5.4% means that €-0.05 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ANI Pharmaceuticals Inc:

  • The MRQ is -5.4%. The company is making a loss. -1
  • The TTM is -2.5%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-5.4%TTM-2.5%-2.9%
TTM-2.5%YOY3.8%-6.3%
TTM-2.5%5Y-9.2%+6.6%
5Y-9.2%10Y-8.4%-0.7%
4.3.1.2. Return on Assets

Shows how efficient ANI Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare ANI Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.8% Return on Assets means that ANI Pharmaceuticals Inc generated €-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ANI Pharmaceuticals Inc:

  • The MRQ is -0.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.8%TTM-0.2%-0.6%
TTM-0.2%YOY0.5%-0.8%
TTM-0.2%5Y-0.8%+0.6%
5Y-0.8%10Y-0.8%-0.1%
4.3.1.3. Return on Equity

Shows how efficient ANI Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare ANI Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -2.4% Return on Equity means ANI Pharmaceuticals Inc generated €-0.02 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ANI Pharmaceuticals Inc:

  • The MRQ is -2.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.4%TTM-1.2%-1.2%
TTM-1.2%YOY1.1%-2.2%
TTM-1.2%5Y-2.1%+1.0%
5Y-2.1%10Y-1.9%-0.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of ANI Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient ANI Pharmaceuticals Inc is operating .

  • Measures how much profit ANI Pharmaceuticals Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare ANI Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ANI Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY5.7%-5.7%
TTM-5Y-0.9%+0.9%
5Y-0.9%10Y1.2%-2.0%
4.3.2.2. Operating Ratio

Measures how efficient ANI Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.41 means that the operating costs are €1.41 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of ANI Pharmaceuticals Inc:

  • The MRQ is 1.414. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.400. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.414TTM1.400+0.015
TTM1.400YOY1.269+0.131
TTM1.4005Y1.459-0.059
5Y1.45910Y1.445+0.014
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of ANI Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if ANI Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.72 means the company has €2.72 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of ANI Pharmaceuticals Inc:

  • The MRQ is 2.725. The company is able to pay all its short-term debts. +1
  • The TTM is 3.347. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.725TTM3.347-0.622
TTM3.347YOY3.478-0.131
TTM3.3475Y3.015+0.331
5Y3.01510Y2.928+0.087
4.4.3.2. Quick Ratio

Measures if ANI Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare ANI Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.18 means the company can pay off €1.18 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ANI Pharmaceuticals Inc:

  • The MRQ is 1.177. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.205. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.177TTM1.205-0.028
TTM1.205YOY1.310-0.105
TTM1.2055Y1.291-0.086
5Y1.29110Y1.246+0.045
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of ANI Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of ANI Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare ANI Pharmaceuticals Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.67 means that ANI Pharmaceuticals Inc assets are financed with 66.6% credit (debt) and the remaining percentage (100% - 66.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ANI Pharmaceuticals Inc:

  • The MRQ is 0.666. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.572. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.666TTM0.572+0.094
TTM0.572YOY0.508+0.064
TTM0.5725Y0.556+0.016
5Y0.55610Y0.554+0.002
4.5.4.2. Debt to Equity Ratio

Measures if ANI Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare ANI Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 199.6% means that company has €2.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ANI Pharmaceuticals Inc:

  • The MRQ is 1.996. The company is just able to pay all its debts with equity.
  • The TTM is 1.454. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.996TTM1.454+0.541
TTM1.454YOY1.041+0.413
TTM1.4545Y1.288+0.167
5Y1.28810Y1.275+0.013
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings ANI Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare ANI Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -29.31 means the investor is paying €-29.31 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ANI Pharmaceuticals Inc:

  • The EOD is -32.473. Based on the earnings, the company is expensive. -2
  • The MRQ is -29.312. Based on the earnings, the company is expensive. -2
  • The TTM is -42.903. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-32.473MRQ-29.312-3.161
MRQ-29.312TTM-42.903+13.591
TTM-42.903YOY135.009-177.912
TTM-42.9035Y130.119-173.022
5Y130.11910Y119.912+10.208
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ANI Pharmaceuticals Inc:

  • The EOD is 24.940. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 22.512. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 30.159. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD24.940MRQ22.512+2.428
MRQ22.512TTM30.159-7.647
TTM30.159YOY12.660+17.499
TTM30.1595Y0.761+29.398
5Y0.76110Y0.691+0.069
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of ANI Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.81 means the investor is paying €2.81 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of ANI Pharmaceuticals Inc:

  • The EOD is 3.115. Based on the equity, the company is fair priced.
  • The MRQ is 2.812. Based on the equity, the company is underpriced. +1
  • The TTM is 2.923. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.115MRQ2.812+0.303
MRQ2.812TTM2.923-0.111
TTM2.923YOY2.616+0.307
TTM2.9235Y2.846+0.077
5Y2.84610Y3.182-0.336
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,283,697
Total Liabilities855,167
Total Stockholder Equity428,530
 As reported
Total Liabilities 855,167
Total Stockholder Equity+ 428,530
Total Assets = 1,283,697

Assets

Total Assets1,283,697
Total Current Assets527,684
Long-term Assets756,013
Total Current Assets
Cash And Cash Equivalents 144,861
Short-term Investments 6,307
Net Receivables 221,726
Inventory 136,782
Other Current Assets 17,975
Total Current Assets  (as reported)527,684
Total Current Assets  (calculated)527,651
+/- 33
Long-term Assets
Property Plant Equipment 56,863
Goodwill 59,990
Intangible Assets 541,834
Long-term Assets  (as reported)756,013
Long-term Assets  (calculated)658,687
+/- 97,326

Liabilities & Shareholders' Equity

Total Current Liabilities193,680
Long-term Liabilities661,487
Total Stockholder Equity428,530
Total Current Liabilities
Short Long Term Debt 9,172
Accounts payable 45,656
Other Current Liabilities 29
Total Current Liabilities  (as reported)193,680
Total Current Liabilities  (calculated)54,857
+/- 138,823
Long-term Liabilities
Long term Debt 614,920
Long-term Liabilities Other 25,606
Long-term Liabilities  (as reported)661,487
Long-term Liabilities  (calculated)640,526
+/- 20,961
Total Stockholder Equity
Total Stockholder Equity (as reported)428,530
Total Stockholder Equity (calculated)0
+/- 428,530
Other
Capital Stock24,852
Common Stock Shares Outstanding 21,108
Net Debt 479,231
Net Invested Capital 1,027,772
Net Working Capital 334,004
Property Plant and Equipment Gross 101,743



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
456,775
456,789
482,232
465,391
462,581
461,190
463,843
480,159
470,454
771,598
744,846
751,334
739,110
760,087
765,224
859,341
889,914
904,422
914,524
920,753
1,287,377
1,283,697
1,283,6971,287,377920,753914,524904,422889,914859,341765,224760,087739,110751,334744,846771,598470,454480,159463,843461,190462,581465,391482,232456,789456,775
   > Total Current Assets 
182,386
187,695
158,662
156,544
165,819
170,321
182,798
191,799
191,384
321,775
301,399
322,399
309,377
344,261
364,753
459,311
497,220
519,816
540,557
555,460
521,297
527,684
527,684521,297555,460540,557519,816497,220459,311364,753344,261309,377322,399301,399321,775191,384191,799182,798170,321165,819156,544158,662187,695182,386
       Cash And Cash Equivalents 
59,673
62,332
20,414
27,702
17,900
7,864
25,073
24,261
15,254
100,300
76,911
63,385
56,281
48,228
67,757
161,707
193,078
221,121
228,597
240,110
144,982
144,861
144,861144,982240,110228,597221,121193,078161,70767,75748,22856,28163,38576,911100,30015,25424,26125,0737,86417,90027,70220,41462,33259,673
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,655
6,943
8,298
6,307
6,3078,2986,9439,655000000000000000000
       Net Receivables 
70,700
72,129
82,379
73,162
83,745
95,793
91,876
92,648
106,714
128,526
131,625
150,410
140,433
165,438
174,713
172,925
178,842
162,079
172,418
166,091
196,361
221,726
221,726196,361166,091172,418162,079178,842172,925174,713165,438140,433150,410131,625128,526106,71492,64891,87695,79383,74573,16282,37972,12970,700
       Inventory 
46,174
48,163
52,902
52,563
59,195
60,803
59,927
67,634
61,684
81,693
83,155
92,545
95,893
105,355
103,654
104,323
106,590
111,196
113,837
125,448
148,042
136,782
136,782148,042125,448113,837111,196106,590104,323103,654105,35595,89392,54583,15581,69361,68467,63459,92760,80359,19552,56352,90248,16346,174
       Other Current Assets 
1,214
1,276
200
300
1,821
300
300
2,575
3,330
3,867
2,182
10,233
11,998
17,153
11,755
12,308
10,690
17,400
16,050
14,001
17,475
17,975
17,97517,47514,00116,05017,40010,69012,30811,75517,15311,99810,2332,1823,8673,3302,5753003001,8213002001,2761,214
   > Long-term Assets 
274,389
269,094
323,570
308,847
296,762
290,869
281,045
288,360
279,070
449,823
443,447
428,935
429,733
415,826
400,471
400,030
392,694
384,606
373,967
365,293
766,080
756,013
756,013766,080365,293373,967384,606392,694400,030400,471415,826429,733428,935443,447449,823279,070288,360281,045290,869296,762308,847323,570269,094274,389
       Property Plant Equipment 
39,754
40,551
40,353
39,937
40,444
41,269
40,767
40,334
39,526
52,671
52,713
43,771
42,830
43,246
43,275
44,371
44,189
44,593
48,526
51,640
56,704
56,863
56,86356,70451,64048,52644,59344,18944,37143,27543,24642,83043,77152,71352,67139,52640,33440,76741,26940,44439,93740,35340,55139,754
       Goodwill 
3,580
3,580
3,580
3,580
3,580
3,580
3,580
3,580
3,580
27,888
28,188
28,221
28,221
28,221
28,221
28,221
28,221
28,221
28,221
28,221
60,426
59,990
59,99060,42628,22128,22128,22128,22128,22128,22128,22128,22128,22128,18827,8883,5803,5803,5803,5803,5803,5803,5803,5803,580
       Intangible Assets 
188,372
180,388
215,619
205,745
198,620
188,511
178,859
180,199
170,141
294,122
281,573
269,593
264,237
251,635
238,791
230,299
219,828
209,009
196,044
183,078
569,825
541,834
541,834569,825183,078196,044209,009219,828230,299238,791251,635264,237269,593281,573294,122170,141180,199178,859188,511198,620205,745215,619180,388188,372
       Other Assets 
42,683
44,575
64,018
59,585
54,118
57,509
57,839
64,247
65,823
75,142
80,573
83,750
85,045
92,724
90,184
87,939
0
0
0
0
0
0
00000087,93990,18492,72485,04583,75080,57375,14265,82364,24757,83957,50954,11859,58564,01844,57542,683
> Total Liabilities 
243,645
243,998
281,061
274,047
267,481
265,490
260,131
288,242
279,051
412,858
398,752
414,376
402,435
421,547
425,742
424,869
435,203
446,823
437,711
440,143
856,579
855,167
855,167856,579440,143437,711446,823435,203424,869425,742421,547402,435414,376398,752412,858279,051288,242260,131265,490267,481274,047281,061243,998243,645
   > Total Current Liabilities 
170,707
61,676
79,356
79,088
75,900
78,565
82,768
89,454
84,872
87,537
79,532
96,312
81,627
99,439
125,825
122,865
134,352
145,477
136,889
139,978
189,933
193,680
193,680189,933139,978136,889145,477134,352122,865125,82599,43981,62796,31279,53287,53784,87289,45482,76878,56575,90079,08879,35661,676170,707
       Short Long Term Debt 
121,740
9,941
11,872
12,329
12,785
13,243
14,438
15,182
15,927
850
850
850
850
850
850
850
850
850
850
850
7,152
9,172
9,1727,15285085085085085085085085085085085015,92715,18214,43813,24312,78512,32911,8729,941121,740
       Accounts payable 
10,953
14,606
12,485
14,209
13,460
11,261
13,769
12,977
11,513
22,967
22,059
27,641
18,992
29,305
32,687
28,505
34,077
36,683
49,430
48,681
60,890
45,656
45,65660,89048,68149,43036,68334,07728,50532,68729,30518,99227,64122,05922,96711,51312,97713,76911,26113,46014,20912,48514,60610,953
       Other Current Liabilities 
16,441
17,046
33,155
28,414
23,362
31,141
32,665
31,966
32,291
35,918
35,670
34,899
33,984
33,399
56,869
54,823
23,939
12,266
414
841
1,283
29
291,28384141412,26623,93954,82356,86933,39933,98434,89935,67035,91832,29131,96632,66531,14123,36228,41433,15517,04616,441
   > Long-term Liabilities 
72,938
182,322
201,705
194,959
191,581
186,925
177,363
198,788
194,179
325,321
319,220
318,064
320,808
322,108
299,917
302,004
300,851
301,346
300,822
300,165
666,646
661,487
661,487666,646300,165300,822301,346300,851302,004299,917322,108320,808318,064319,220325,321194,179198,788177,363186,925191,581194,959201,705182,32272,938
       Long term Debt 
64,873
175,808
188,094
177,879
175,161
172,443
168,985
189,525
186,063
286,520
286,307
286,095
285,882
285,669
285,457
285,244
285,032
284,819
284,607
284,394
618,211
614,920
614,920618,211284,394284,607284,819285,032285,244285,457285,669285,882286,095286,307286,520186,063189,525168,985172,443175,161177,879188,094175,80864,873
       Other Liabilities 
2
7
0
1
200
201
6
0
0
31,016
32,053
30,970
33,445
35,058
13,258
12,029
0
0
0
0
0
0
00000012,02913,25835,05833,44530,97032,05331,0160062012001072
       Long-term Liabilities Other 
8,065
6,514
13,611
17,080
0
0
0
0
0
31,000
32,053
30,958
33,434
36,439
14,460
16,760
15,819
16,527
16,215
15,771
27,119
25,606
25,60627,11915,77116,21516,52715,81916,76014,46036,43933,43430,95832,05331,0000000017,08013,6116,5148,065
       Deferred Long Term Liability 
1,200
800
700
600
600
500
400
400
300
800
800
700
700
600
0
500
0
0
0
0
0
0
00000050006007007008008003004004005006006007008001,200
> Total Stockholder Equity
213,130
212,791
201,171
191,344
195,100
195,700
203,712
191,917
191,403
358,740
346,094
336,958
336,675
338,540
339,482
434,472
454,711
457,599
476,813
480,610
430,798
428,530
428,530430,798480,610476,813457,599454,711434,472339,482338,540336,675336,958346,094358,740191,403191,917203,712195,700195,100191,344201,171212,791213,130
   Common Stock
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
0
0
0
0
0
0
0000002111111111111111
   Retained Earnings 
22,419
17,584
10,565
-1,771
-1,337
-4,972
-4,886
-18,992
-23,439
-47,765
-68,300
-83,630
-92,636
-97,286
-96,252
-90,414
-80,880
-80,132
-62,331
-65,025
-89,597
-100,279
-100,279-89,597-65,025-62,331-80,132-80,880-90,414-96,252-97,286-92,636-83,630-68,300-47,765-23,439-18,992-4,886-4,972-1,337-1,77110,56517,58422,419
   Accumulated Other Comprehensive Income 0000000000000000000000
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue614,376
Cost of Revenue-250,210
Gross Profit364,166364,166
 
Operating Income (+$)
Gross Profit364,166
Operating Expense-612,158
Operating Income2,218-247,992
 
Operating Expense (+$)
Research Development44,581
Selling General Administrative249,636
Selling And Marketing Expenses-
Operating Expense612,158294,217
 
Net Interest Income (+$)
Interest Income-
Interest Expense-17,602
Other Finance Cost-0
Net Interest Income-17,602
 
Pretax Income (+$)
Operating Income2,218
Net Interest Income-17,602
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-22,2129,046
EBIT - interestExpense = -17,602
-18,522
-920
Interest Expense17,602
Earnings Before Interest and Taxes (EBIT)--4,610
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-22,212
Tax Provision--3,690
Net Income From Continuing Ops-18,522-18,522
Net Income-18,522
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-6,82817,602
 

Technical Analysis of ANI Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of ANI Pharmaceuticals Inc. The general trend of ANI Pharmaceuticals Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine ANI Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ANI Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 58.50 < 60.00 < 60.00.

The bearish price targets are: 51.00 > 51.00 > 51.00.

Tweet this
ANI Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ANI Pharmaceuticals Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ANI Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartANI Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ANI Pharmaceuticals Inc. The current adx is .

ANI Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartANI Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Stochastic Oscillator ChartANI Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartANI Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartANI Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Williams %R ChartANI Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Average True Range (ATR) ChartANI Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartANI Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartANI Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ANI Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-31STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-25ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

ANI Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ANI Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose56.000
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of ANI Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on ANI Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about ANI Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ANI Pharmaceuticals Inc

I send you an email if I find something interesting about ANI Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about ANI Pharmaceuticals Inc.

Receive notifications about ANI Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.